ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca is making a small bet on tumor-bursting oncolytic viruses. The drug company is paying the French biotech firm Transgene $10 million to make five engineered vaccinia viruses that are designed to infect cancer cells and spur the body’s immune system to attack tumors. AstraZeneca suggests it will test the ability of these viruses to boost the efficacy of its existing checkpoint inhibitor therapies. Transgene may earn $3 million more in preclinical milestones and an undisclosed license fee for any viruses AstraZeneca chooses to develop.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter